AI and the Pharmaceutical Industry — 2026-10-11 (Sun)

Overview

Today's coverage is limited to three items, none of which involves a disclosed amount. The most significant is Tempus AI's expanded collaboration with Merck and Moderna. In personalized neoantigen therapy, a core area of drug discovery, the relationship between an AI company and two major pharmaceutical firms has deepened. Separately, a CRB survey points to slow AI adoption in regulated biopharma operations, indicating a gap between investment enthusiasm and implementation on the ground.

By Category

All three items fall under enterprise-wide AI infrastructure and governance.

The expanded collaboration between Tempus AI, Merck, and Moderna extends existing work centered on personalized neoantigen therapy. The headline does not make clear how far the expansion goes, but it can reasonably be read as an investment that deepens an existing partnership.

The partnership between Beijing Haizhi and Jointown aims to upgrade pharmaceutical distribution. The AI use here sits on the distribution side rather than within pharmaceutical companies themselves, which shows AI partnerships spreading into the supply chain.

The CRB survey reports that AI adoption is lagging in regulated biopharma operations. The headline alone does not reveal the survey's scope or the degree of the delay. Governance and regulatory compliance may be constraining adoption, but there is no basis to say so definitively.

Reading the Investment Map

No deals involving disclosed amounts were reported today.

What to Watch

Whether additional details on the scope or terms of the expanded Tempus AI, Merck, and Moderna collaboration are disclosed. 2. Whether companies emerge that are advancing AI adoption in regulated manufacturing and quality functions, in response to the adoption delays the CRB survey identified.